Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VITESSE Viaskin Peanut patch trial in children with peanut allergy
NL-OMON60814Phase 3Active, not recruiting
- Sponsor
- DBV Technologies
- Start
- Jan 2024
- Modality
- Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in peanut allergy comparing DBV712 250 μg with Placebo (2 arms). Primary endpoints: Percentage of treatment responders at Month 12 and Safety and tolerability. Started Jan 2024; status: active, not recruiting.
02
Drugs
DBV712 Viaskin®
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NL-OMON60814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60814.